METHODS	Antiretroviral-nave patients who achieved a viral load < 50 HIV-1 RNA copies/ml after induction therapy with twice-daily ( bid ) lopinavir/ritonavir ( LPV/r ) and fixed-dose zidovudine ( ZDV ) / lamivudine ( 3TC ) ( CBV ) were randomly assigned to continue CBV/LPV/r or switch to fixed-dose ZDV/3TC/abacavir ( TZV ) .\